ClinicalTrials.gg
RecruitingNCT03031210Updated Nov 18, 2026

Twice Daily Treatment With Amoxicillin for Non-severe Community Acquired Pneumonia.

A Phase 2/3 interventional study of Amoxicillin in Community-acquired Pneumonia, sponsored by St. Justine's Hospital. Recruiting at 1 site in Canada. Open to participants aged 3 Months to 18 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-11-18.

Sponsored by St. Justine's Hospital · Phase 2/3, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Jun 2017; still recruiting 9 years 5 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2/3
Study type
Interventional
Enrollment
1,370
Allocation
Randomized
Ages
3 Months to 18 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 12 studies testing amoxicillin in Community-Acquired Pneumonia — 5 open to participants now, 5 under way, 2 of them phase 3. Amoxicillin · Community-Acquired Pneumonia.

Planned enrollment
Largest of 12
1,370 · median 243
Started
2017
the only one that year
Phase 2/3
Only one
of the 12
Registered
5th of 12
by date
Lead sponsor
1 of 12
St. Justine's Hospital

Among the 12 studies testing amoxicillin in Community-Acquired Pneumonia, this one has the largest planned enrollment, is the only one that started in 2017, is the only one in phase 2/3, and was the 5th registered.

Community-Acquired Pneumonia

325 studies on the registry are indexed under Community-Acquired Pneumonia; 77 are open to participants now.

Browse Community-Acquired Pneumonia studies →

Open to participants now

5 of the 12 studies testing amoxicillin in Community-Acquired Pneumonia are open now, in 4 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 5 open studies →

About amoxicillin

Amoxicillin: first FDA approval 1974 (AMOXIL). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 41 Community-Acquired Pneumonia studies recruiting now, 29 (71%) set no upper age limit and 9 (22%) stop at 75 or younger; 13 take children under 18; 5 take healthy volunteers.

This study: 3 Months to 18 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 12 studies testing amoxicillin in Community-Acquired Pneumonia, or all of them as a file.
02

Study summary

The aim of this study will be to evaluate whether a twice-daily antibiotic regimen is non-inferior to a thrice-daily regimen for the treatment of non-severe community acquired pneumonia in children presenting at a paediatric Emergency Department (ED).

Read the detailed description

A single-center, non-blinded, pragmatic, randomized-controlled, non-inferiority clinical trial will be conducted in an urban, university-affiliated, tertiary care pediatric hospital ED. All patients three months old to 18 years of age who had symptoms and signs suggestive of non-severe community acquired pneumonia based on respiratory complaints and a pulmonary infiltrate identified by trained paediatricians or emergency physicians will be eligible to the present study. Study participants will be randomly allocated to receive either amoxicillin (90mg/kg per day) in twice or thrice daily regimen. Primary outcome will be treatment failure within 10 days of enrolment as defined by hospitalisation, need for a change in antibiotic (persistence of fever at 72 hours, clinical deterioration, comorbid condition or development of serious adverse reactions) and death. ED revisits within 72 hours, second course of antibiotic and clinical recurrence rates will be evaluated in the follow-up assessments as well as percent of adverse events encountered, number of days missed (work, school or daycare), coverage vaccination rate, protocol adherence and patient and parental satisfaction. The primary analysis will use an intention-to-treat approach. Per-protocol analysis will also be carried to compare the failure rate. Accounting to a maximal 10% drop-off rate, a sample size of 685 participants per arm was calculated to have a power of 90% to identify a difference of ≤ 5% with an alpha value of 0.05.

03

Conditions studied

  • Community-acquired Pneumonia

Keywords

  • Non-severe community-acquired pneumonia
  • Amoxicillin treatment
  • Twice daily antibiotic regimen
04

Who can participate

Ages eligible
3 Months to 18 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • All patients 3 months to 18 years of age attending the pediatric ED and diagnosed with a non-severe pneumonia, will be considered for enrolment. More precisely, the following inclusion criteria will be required:

    1. Presence of respiratory symptoms (cough and/or dyspnea)
    2. Presence of signs of pneumonia (tachypnea, abnormal breath sounds, crackles)
    3. Presence of fever
    4. Positive chest radiography as interpreted by the treating physician

Exclusion criteria

Exclusion Criteria:

  • Any danger signs associated with pneumonia (severe indrawing, shock or severe dehydration, empyema, important pleural effusion, pulmonary abcess or pneumatocoele)
  • History of anaphylactic or allergic reaction to penicillin or amoxicillin according to the treating physician.
  • History of a serious nonimmunoglobulin E-mediated reactions (eg, Stevens-Johnson syndrome or toxic epidermal necrolysis) attributed to amoxicilin.
  • Caregiver unable to provide consent (language barrier or lack of caregiver presence)
  • Underlying unstable chronic illness (ie. cystic fibrosis, immune suppression, active tuberculosis, bronchiectasis or active pulmonary )
  • Persistent/chronic pneumonia syndromes (with symptoms for >2 weeks), suspected by the physician to be caused by atypical pathogens, hospital- acquired pneumonia (been hospitalized within 2 weeks prior to enrolment), aspiration pneumonia or recurrent pneumonias.
  • Any history of receiving amoxicillin within the past month
  • Need hospitalisation for any other reasons (ie. persistent vomiting, severe life-threatening infection such as septicaemia or meningitis requiring intravenous antimicrobial agents)
  • Previous participation in study
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Phase 2 / Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Investigator, Outcomes assessor)
Enrollment
1,370 participants (estimated)

Study arms

  • Experimental
    Twice a day regimen

    Patients will received a prescription of amoxicillin (90mg/kg/day) divided in two doses daily.

    Drug: Amoxicillin

  • Active comparator
    Thrice a day regimen

    Patients will received a prescription of amoxicillin (90mg/kg/day) divided in three doses daily.

    Drug: Amoxicillin

Interventions

  • (90 mg/kg/day) twice daily

    Also known as: Amoxil

06

What researchers measure

Primary outcomes

  1. Clinical failure within 10 days of enrolment

    As a primary outcome, clinical failure will be defined by any of the following occurring within 10 days of enrolment: * Death or hospitalisation * A need for a change in antibiotic according to the treating physician. In our settings, common reasons to change antibiotic are: * Persistence of fever at 72h * Clinical deterioration: • Clinical deterioration will include the development of lower chest-wall indrawing, central cyanosis, stridor while calm, or danger signs as defined by: inability to drink or breastfeed, convulsions, persistent vomiting, lethargy, or unconsciousness at any time during a child's treatment. * Development of a comorbid condition such as a meningitis, bacteriemia, osteomyelitis or septic arthritis * Allergic reaction

    Time frame: Day 10 (after enrolment)

Secondary outcomes

  1. Emergency department revisit within 72 hours

    Return to the emergency department in the following 72 hours

    Time frame: 72 hours

  2. Second course of antibiotic

    Necessity of second course of antibiotics

    Time frame: 1 month

  3. Clinical recurrence

    Another diagnosis of pneumonia

    Time frame: 1 month

  4. Adverse events

    Any adverse event

    Time frame: 10 days

  5. Number of working days missed by caregivers or school/daycare days missed by patients

    Total number of days missed by caregivers or school/daycare days missed by the parents

    Time frame: 1 month

  6. Patient's and parents satisfaction with the discharge instructions' provided and the ease of administration

    Measured on a likert scale through a telephone survey

    Time frame: 10 days

07

Study locations

1 of 1 sites recruiting
  • CHU Sainte-Justine
    Montreal, Quebec H3T1C5, Canada
    Recruiting
    • Jocelyn Gravel, MD · Contactgraveljocelyn@hotmail.com · 514-345-4931
    • Ariane Boutin, MD · Contactarianeboutin@gmail.com · 514-345-4931
    • Jocelyn Gravel, MD · Principal investigator
    • Boutin Ariane, MD · Principal investigator
    • Benoit Carriere, MD · Sub investigator
    • Marc Lebel, MD · Sub investigator
    • Michel Roy, MD · Sub investigator
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Jun 2017 (actual). Primary completion is estimated for Jun 2027, 119 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 23, 2017
First posted
Jan 25, 2017
StartActual
Jun 11, 2017
Primary completionEst.
Jun 1, 2027
CompletionEst.
Jun 1, 2027
Last update
Nov 18, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Minor edits
Nothing that changes what the study is or who can join. Edited: verification date
1 update, last Nov 18, 2026
Show all 1 update
  1. Nov 18, 2026
    Minor edits only
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT03031210
Responsible party
Jocelyn Gravel (Principal investigator, St. Justine's Hospital) — Principal investigator
First posted
Jan 25, 2017
Start date
Jun 11, 2017
Primary completion
Jun 1, 2027 (estimated)
Completion
Jun 1, 2027 (estimated)
Last update
Nov 18, 2026

Study contacts

Jocelyn Gravel, MD
Contact
graveljocelyn@hotmail.com
514-345-4931 ext. 2559
Ariane Boutin, MD
Contact
arianeboutin@gmail.com
514-345-4931
Jocelyn Gravel, MD
principal investigator · Sainte-Justine Hospital

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Amoxicillin

Start the discussion